Information de reference pour ce titreAccession Number: | 00149457-201802000-00010.
|
Author: | Ross, C. 1; Rangarajan, S. 2; Karimi, M. 3; Toogeh, G. 4; Apte, S. 5; Lissitchkov, T. 6; Acharya, S. 7; Manco-Johnson, M. J. 8; Srivastava, A. 9; Brand, B. 10; Schwartz, B. A. 11; Knaub, S. 12; Peyvandi, F. *,13
|
Institution: | (1)Department of Hematology St John's Medical College and Hospital Bangalore India (2)Centre For Haemostasis and Thrombosis St Thomas' Hospital London UK (3)Hematology Research Center Nemazee Hospital Shiraz University of Medical Sciences Shiraz Iran (4)Thrombosis Hemostasis Research Center Tehran University of Medical Sciences Tehran Iran (5)Sahyadri Speciality Hospital Pune Maharashtra India (6)Department of Hemorrhagic Diathesis and Anemia Specialized Hospital for Active Treatment (SHAT) 'Joan Pavel' Sofia Bulgaria (7)Cohen Children's Medical Center of New York Northwell Health New Hyde Park NY USA (8)Hemophilia and Thrombosis Center University of Colorado Anschutz Medical Campus Aurora CO USA (9)Department of Haematology Christian Medical College Vellore India (10)Department of Haematology University Hospital Zurich Zurich Switzerland (11)Clinical Research and Development Octapharma Hoboken NJ USA (12)Research and Development Department Octapharma Lachen Switzerland (13)Angelo Bianchi Bonomi Hemophilia and Thrombosis Centre Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and Luigi Villa Foundation Department of Pathophysiology and Transplantation Universita degli Studi di Milano Milan Italy
|
Title: | Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency.[Miscellaneous Article]
|
Source: | Journal of Thrombosis & Haemostasis. 16(2):253-261, February 2018.
|
Author Keywords: | afibrinogenemia; comparative study; congenital; fibrinogen; pharmacokinetics.
|
References: | 1. Mosesson MW, Siebenlist KR, Meh DA. The structure and biological features of fibrinogen and fibrin. Ann N Y Acad Sci 2001; 936: 11-30.
2. Miesbach W, Schenk J, Alesci S, Lindhoff-Last E. Comparison of the fibrinogen Clauss assay and the fibrinogen PT derived method in patients with dysfibrinogenemia. Thromb Res 2010; 126: e428-33.
3. Acharya SS, Dimichele DM. Rare inherited disorders of fibrinogen. Haemophilia 2008; 14: 1151-8.
4. Peyvandi F, Bolton-Maggs PH, Batorova A, De Moerloose P. Rare bleeding disorders. Haemophilia 2012; 18(Suppl. 4): 148-53.
5. Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004; 104: 1243-52.
6. Peyvandi F, Haertel S, Knaub S, Mannucci PM. Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia. J Thromb Haemost 2006; 4: 1634-7.
7. Bornikova L, Peyvandi F, Allen G, Bernstein J, Manco-Johnson MJ. Fibrinogen replacement therapy for congenital fibrinogen deficiency. J Thromb Haemost 2011; 9: 1687-704.
8. Manco-Johnson MJ, Dimichele D, Castaman G, Fremann S, Knaub S, Kalina U, Peyvandi F, Piseddu G, Mannucci P; Fibrinogen Concentrate Study Group . Pharmacokinetics and safety of fibrinogen concentrate. J Thromb Haemost 2009; 7: 2064-9.
9. Sorensen B, Bevan D. A critical evaluation of cryoprecipitate for replacement of fibrinogen. Br J Haematol 2010; 149: 834-43.
10. Burnouf T, Goubran HA, Radosevich M, Sayed MA, Gorgy G, El-Ekiaby M. A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system. Vox Sang 2006; 91: 56-62.
11. Burnouf T, Caron C, Radosevich M, Goubran HA, Goudemand J, El-Ekiaby M. Properties of a concentrated minipool solvent-detergent treated cryoprecipitate processed in single-use bag systems. Haemophilia 2008; 14: 956-62.
12. CSL Behring . Fibrinogen concentrate. http://- ouverture dans une nouvelle fenêtre http://www.allaboutbleeding.com/...- ouverture dans une nouvelle fenêtre [Accessed: 27 October 2016].
13. Solomon C, Wendt M. The factor in the license: in reference to "use of prothrombin complex concentrates and fibrinogen concentrates in the perioperative setting: a systematic review". Transfus Med Rev 2014; 28: 31.
14. CSL Behring . RiaSTAP(R) prescribing information. [Accessed: 27 October 2016].
15. Kreuz W, Meili E, Peter-Salonen K, Dobrkovska A, Devay J, Haertel S, Krzensk U, Egbring R. Pharmacokinetic properties of a pasteurised fibrinogen concentrate. Transfus Apher Sci 2005; 32: 239-46.
16. Kreuz W, Meili E, Peter-Salonen K, Haertel S, Devay J, Krzensk U, Egbring R. Efficacy and tolerability of a pasteurised human fibrinogen concentrate in patients with congenital fibrinogen deficiency. Transfus Apher Sci 2005; 32: 247-53.
17. Octapharma . Efficacy and safety study of Octafibrin for on-demand treatment of acute bleeding and to prevent bleeding during and after surgery (NCT02267226). https://clinicaltrials.gov/ct2/s...- ouverture dans une nouvelle fenêtre [Accessed: 27 October 2016].
18. Octapharma . Study to assess the efficacy, safety and pharmacokinetic of Octafibrin in paediatric subjects with fibrinogen deficiency (NCT02408484). https://clinicaltrials.gov/ct2/s...- ouverture dans une nouvelle fenêtre [Accessed: 24 July 2017].
19. Kalina U, Stohr HA, Bickhard H, Knaub S, Siboni SM, Mannucci PM, Peyvandi F. Rotational thromboelastography for monitoring of fibrinogen concentrate therapy in fibrinogen deficiency. Blood Coagul Fibrinolysis 2008; 19: 777-83.
20. Negrier C, Rothschild C, Goudemand J, Borg JY, Claeyssens S, Alessi MC, Jaffry AC, Teboul C, Padrazzi B, Waegemans T. Pharmacokinetics and pharmacodynamics of a new highly secured fibrinogen concentrate. J Thromb Haemost 2008; 6: 1494-9.
21. Solomon C, Groner A, Ye J, Pendrak I. Safety of fibrinogen concentrate: analysis of more than 27 years of pharmacovigilance data. Thromb Haemost 2015; 113: 759-71.
|
Language: | English.
|
Document Type: | CLINICAL HAEMOSTASIS AND THROMBOSIS.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 1538-7933
|
NLM Journal Code: | 101170508
|
DOI Number: | https://dx.doi.org/10.1111/jth.1...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|